Non-alcoholic fatty liver disease (NAFLD) can derive in non-alcoholic steatohepatitis (NASH), which can further progress to cirrhosis and hepatocellular carcinoma (HCC). By performing experiments in a variety of mouse models of NASH, Malehmir et al. demonstrate that platelets number, activation and aggregation are increased. This finding was also validated in patient samples. Most importantly, antiplatelet therapy reduced NASH and HCC development in mice and had promising results in a small pilot study. This study strongly suggests that antiplatelet strategies could potentially be used to prevent or revert NASH and derived HCC.
(Mohsen Malehmir et al. – Nature Medicine, 1 April 2019)